Patient-reported outcomes and factors associated with early discontinuation of adjuvant endocrine therapy in premenopausal women with breast cancer

Abstract

Background: Adjuvant endocrine therapy (AET) reduces risks of recurrence and death in women with hormone receptor-positive breast cancer (BC). Despite these benefits, many women discontinue AET prematurely due to symptoms. We have previously demonstrated associations between patient-reported outcomes (PRO) and clinical characteristics with early discontinuation (DC) in a clinic-based cohort. Here, we report PRO and factors associated with early DC among the premenopausal participants.